Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELZNASDAQ:CURNASDAQ:FRTXNASDAQ:KLTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELZCreative Medical Technology$2.65-0.7%$2.23$1.69▼$6.90$6.90M2.0456,824 shs29,215 shsCURNeuralstem$0.73-0.6%$1.06$1.10▼$13.78$1.52M1.81236,278 shs27,836 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsKLTOKlotho Neurosciences$1.33+16.7%$0.67$0.11▼$3.91$37.04M11.0839.03 million shs6.90 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELZCreative Medical Technology0.00%+1.13%+12.13%+22.94%-29.65%CURNeuralstem0.00%+3.57%+6.57%+12.58%-83.85%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%-0.53%KLTOKlotho Neurosciences0.00%+58.31%+456.10%+591.75%+113,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELZCreative Medical TechnologyN/AN/AN/AN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELZCreative Medical Technology 0.00N/AN/AN/ACURNeuralstem 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AKLTOKlotho Neurosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELZCreative Medical Technology$10K686.35N/AN/A$3.63 per share0.73CURNeuralstem$260K5.86N/AN/A$6.64 per share0.11FRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56KLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELZCreative Medical Technology-$5.49M-$3.810.00N/AN/AN/A-85.26%-81.49%8/8/2025 (Estimated)CURNeuralstem-$4.93MN/A0.00∞N/A-39,417.64%-170.51%-110.16%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AKLTOKlotho Neurosciences-$6.15M-$0.360.00∞N/AN/A-1,779.01%-275.01%N/ALatest CUR, CELZ, KLTO, and FRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/9/2025Q1 2025CELZCreative Medical Technology-$0.52-$0.83-$0.31-$0.83N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELZCreative Medical TechnologyN/AN/AN/AN/AN/ACURNeuralstemN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELZCreative Medical TechnologyN/A27.4327.42CURNeuralstemN/A2.532.53FRTXFresh Tracks TherapeuticsN/AN/AN/AKLTOKlotho NeurosciencesN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELZCreative Medical Technology1.42%CURNeuralstem38.30%FRTXFresh Tracks Therapeutics25.04%KLTOKlotho Neurosciences20.07%Insider OwnershipCompanyInsider OwnershipCELZCreative Medical Technology1.80%CURNeuralstem5.38%FRTXFresh Tracks Therapeutics0.23%KLTOKlotho Neurosciences26.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELZCreative Medical Technology52.59 million2.54 millionNot OptionableCURNeuralstem62.10 millionN/ANot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableKLTOKlotho NeurosciencesN/A32.49 million23.82 millionN/ACUR, CELZ, KLTO, and FRTX HeadlinesRecent News About These CompaniesKlotho Neurosciences (NASDAQ:KLTO) Rating Increased to Sell at Wall Street ZenJuly 5 at 2:26 AM | americanbankingnews.comKLTO - Klotho Neurosciences Inc Chart - MorningstarJuly 2, 2025 | morningstar.comMKlotho Neurosciences Begins Manufacturing Gene Therapy for ALSJuly 2, 2025 | theglobeandmail.comKlotho Neurosciences moves forward with manufacturing gene therapy to treat amyotrophic lateral sclerosisJuly 1, 2025 | pharmabiz.comPKlotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALSJune 30, 2025 | prnewswire.comKlotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived PopulationJune 24, 2025 | prnewswire.comKLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMSJune 18, 2025 | prnewswire.comKLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENTJune 16, 2025 | prnewswire.comBest Penny Stocks To Research - June 10thJune 10, 2025 | marketbeat.comKlotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?June 10, 2025 | forbes.comKlotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The MoonJune 10, 2025 | msn.comPenny Stocks To Watch Today - June 9thJune 9, 2025 | marketbeat.comPromising Small Cap Stocks Worth Watching - June 9thJune 9, 2025 | marketbeat.comKLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")June 9, 2025 | prnewswire.comNasdaq Top 5 Premarket Losers: Healthcare Triangle, Klotho Neurosciences, New Fortress Energy, NanoVibronix, MDJMMay 15, 2025 | msn.comProtein discovered that boosts lifespan, muscle, and brain power with just one doseMay 10, 2025 | earth.comEKlotho: A protein that promotes healthy aging and improves longevityMay 9, 2025 | msn.comBoosting Klotho Protein Slows Aging and Enhances HealthMay 9, 2025 | neurosciencenews.comNKlotho Neurosciences faces Nasdaq delisting riskApril 23, 2025 | investing.comKlotho Neurosciences to Acquire SkyBell Tech SubsidiaryApril 3, 2025 | investing.comKlotho Neurosciences, Inc. (KLTO)February 2, 2025 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build BeginsTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomDollar Down 10%? These 3 Stocks Could SoarBy Chris Markoch | July 1, 2025View Dollar Down 10%? These 3 Stocks Could SoarNew Catalysts to Drive NVIDIA’s Stock Price Even HigherBy Thomas Hughes | June 16, 2025View New Catalysts to Drive NVIDIA’s Stock Price Even HigherIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockCUR, CELZ, KLTO, and FRTX Company DescriptionsCreative Medical Technology NASDAQ:CELZ$2.65 -0.02 (-0.75%) Closing price 03:59 PM EasternExtended Trading$2.63 -0.02 (-0.72%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Neuralstem NASDAQ:CURNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Klotho Neurosciences NASDAQ:KLTO$1.33 +0.19 (+16.67%) As of 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
